首页> 外文期刊>JAMA dermatology >Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy
【24h】

Palliative Therapy for Recalcitrant Cutaneous T-Cell Lymphoma of the Hands and Feet With Low-Dose, High Dose-Rate Brachytherapy

机译:低剂量,高剂量率近距离放射疗法治疗手脚顽固性皮肤T细胞淋巴瘤

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

IMPORTANCE Cutaneous T-cell lymphoma (CTCL) of the hands and feet can be challenging to treat and cause significant disability for patients. Although CTCL is a highly radiosensitive tumor, the complex topography of acral surfaces presents challenges to achieving homogeneous superficial dosing of traditional electron beam therapy. In addition, traditional dosing may result in substantial acute cutaneous toxic effects. Recent reports demonstrate that low-dose palliative radiotherapy may be as effective as traditional regimens in CTCL. High dose-rate (HDR) brachytherapy allows for control of the depth of radiation penetration over complex curved surfaces. This study investigated the role of low-dose HDR brachytherapy for acral CTCL lesions.
机译:重要事项手和脚的皮肤T细胞淋巴瘤(CTCL)可能难以治疗,并导致患者严重残疾。尽管CTCL是高度放射敏感性的肿瘤,但复杂的椎体表面地形对实现传统电子束治疗的均匀表面剂量提出了挑战。另外,传统的剂量可能导致大量的急性皮肤毒性作用。最近的报道表明,小剂量姑息性放疗可能与CTCL的传统疗法一样有效。高剂量率(HDR)近距离放射治疗可以控制复杂曲面上辐射穿透的深度。这项研究调查了低剂量HDR近距离放射疗法在急性CTCL病变中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号